Best Peptides for Sleep: DSIP, Sermorelin, Epitalon - What the Evidence Supports

Key takeaways

• No peptide is a proven treatment for insomnia. The benchmark is cognitive behavioral therapy for insomnia (CBT-I), the only insomnia treatment the American Academy of Sleep Medicine recommends strongly; across 20 trials it got people to sleep about 19 minutes sooner and cut time awake at night by about 26 minutes.
• When a drug is needed, the FDA-approved orexin antagonists (suvorexant, lemborexant, daridorexant) were tested in roughly 800 to 1,850 adults each; at their higher doses, lemborexant and daridorexant cut time awake by about 18 to 25 minutes a night more than placebo. Orexin is itself a peptide; these drugs block it.
• Sermorelin ranks first among peptides only because it is legal and the physiology is real: pulses of GHRH raised slow-wave sleep from 14% to 20% of the night in seven young men. No sermorelin trial has measured sleep objectively, a GHRH-analog trial in older adults found sleep unchanged, and GHRH impaired sleep in young women.
• DSIP is the only peptide ever tested in insomniacs, in small 1981 to 1992 trials that did not replicate; FDA's committee voted 6 to 7 against it in July 2026. Epitalon, CJC-1295 and ipamorelin have no sleep study at all. MK-677 improved deep and REM sleep in a small 1997 study but is not a peptide and is on FDA's safety-risk list.
• Loud snoring with pauses in breathing, restless legs, sudden sleep attacks, or insomnia three nights a week for three months are reasons to see a sleep clinician, not to buy a vial.

Search for a peptide for sleep and you will be offered DSIP, sermorelin, epitalon and a CJC-1295 and ipamorelin "sleep stack", usually with a dosing chart. This guide sets the bar with the treatments that have strong evidence for insomnia, then grades each peptide by its human sleep data and by whether a US pharmacy can legally dispense it in October 2026. The profiles go deeper on DSIP, sermorelin and CJC-1295 with ipamorelin, and two short guides cover DSIP dosage and CJC-1295 for sleep.

Start with the benchmark: what works for insomnia

Cognitive behavioral therapy for insomnia. CBT-I is a structured program that combines several of sleep restriction, stimulus control, cognitive therapy, relaxation and sleep hygiene. The American Academy of Sleep Medicine's 2021 guideline gives multicomponent CBT-I its only strong recommendation for chronic insomnia in adults and advises against sleep hygiene on its own (Edinger 2021). A meta-analysis of 20 randomized trials in 1,162 adults found that, against inactive controls, CBT-I shortened the time to fall asleep by 19 minutes, cut time awake after falling asleep by 26 minutes and raised sleep efficiency by about 10 percentage points; total sleep time rose by only about 8 minutes, not a statistically clear difference, and the gains appeared to last (Trauer 2015).

Medication. The academy's 2017 drug guideline, written before two of the newer drugs were approved, gave weak recommendations to several prescription hypnotics, including suvorexant for staying asleep, zolpidem, eszopiclone, doxepin and ramelteon, and suggested that clinicians not use trazodone, diphenhydramine, melatonin, L-tryptophan or valerian for chronic insomnia (Sateia 2017).

The orexin antagonists. Orexin is a peptide made in the hypothalamus that keeps the brain awake; people who lose the neurons that make it develop narcolepsy. Three FDA-approved drugs block its receptors, and their trials measured sleep directly in large numbers of people with insomnia.

Two caveats. The suvorexant trial tested 30 and 40 mg, above the doses FDA approved, and all three drugs can leave some people drowsy the next day. And none of these effects is dramatic: the gains over placebo or inactive control are measured in tens of minutes a night, plus, with CBT-I, a change that lasts after treatment stops. Every row rests on randomized trials in people with insomnia against an inactive control. That is the bar, and no peptide has been tested that way.

How we ranked

We graded each compound on human evidence for a sleep outcome, using the site's A to D scale: A for adequately powered randomized trials, B for small, short or uncontrolled human trials, C for indirect human evidence such as the effects of a related hormone, D for animal, cell or no data. We then sorted by legality in the United States as of October 2026, using our legal tracker, because a compound no pharmacy may prepare has no legal version to recommend. Safety and cost broke ties; popularity did not count. A grade describes the evidence, not a recommendation.

The ranking at a glance

Costs are from our cost guide as of October 2026. "None legal" means no US pharmacy may compound it, so any price you see is for an unregulated vial.

1. Sermorelin: the legal option, with physiology rather than proof

What it does. Sermorelin is the first 29 amino acids of growth hormone-releasing hormone (GHRH), injected under the skin at bedtime to trigger the pituitary's own growth hormone pulse. Its sleep claim comes from GHRH research, not from sermorelin trials.

The key evidence. In seven healthy young men, four 50 mcg intravenous pulses of GHRH at 10 p.m., 11 p.m., midnight and 1 a.m. raised the share of the night spent in slow-wave sleep from 14.0% to 20.2% and blunted overnight cortisol (Steiger 1992). The delivery pattern mattered: the same 200 mcg given as four pulses increased slow-wave and REM sleep against placebo, while a continuous infusion had no significant effect (Marshall 1996). Two findings cut the other way. In the longest GHRH-analog trial, 10 women and 9 men aged 55 to 71 injected a stabilized analog nightly for 16 weeks, and sleep quality by questionnaire was unaffected in both sexes (Khorram 1997). In healthy young women, GHRH pulses reduced REM sleep at the lower dose and stage 4 deep sleep at the higher dose, and the authors concluded that systemic GHRH impairs sleep in women (Mathias 2007).

Grade. C: positive in young men given intravenous pulses, neutral in older adults, negative in young women. A single nightly injection under the skin is not the protocol that worked, and no sermorelin trial has measured sleep with polysomnography in the adults it is sold to.

Legal status and cost. Compoundable on prescription, because sermorelin was the active ingredient of an approved drug (Geref). About $150 to $400 a month through telehealth.

Who it is for. An adult with a documented low IGF-1, prescribed by a clinician who measures IGF-1 before and after, for whom better sleep would be a welcome side effect rather than the goal. It is not an insomnia treatment, and women should not expect deeper sleep from it; see sermorelin for women.

2. DSIP: the only peptide tested in insomnia, and it did not hold up

What it does. Delta sleep-inducing peptide (emideltide) is a nine-amino-acid peptide isolated from rabbits in 1977, with no identified gene or receptor (see the DSIP profile); in human plasma it lasts about eight minutes (FDA emideltide review 2026).

The key evidence. One Swiss investigator reported that intravenous DSIP improved sleep in groups of 6 to 18 chronic insomniacs in the 1980s; FDA's 2026 review noted that the positive studies were small and lacked an adequate control group, comparing patients with their own baseline nights or with outside normal sleepers. Independent double-blind tests did not confirm the effect. A crossover in six insomniacs found no significant difference from placebo, and in 16 chronic insomniacs given 25 nmol/kg or placebo on three afternoons, the effects were weak, possibly a chance change in the placebo group, and the authors concluded DSIP was not likely to be of major therapeutic benefit (Bes 1992). In the studies FDA identified, 209 people received 25 to 150 nmol/kg intravenously for 1 to 15 days; FDA called the insomnia evidence inconclusive and at best preliminary, and found no data for the subcutaneous route sellers use (FDA emideltide review 2026).

The dose gap. The studied 25 to 30 nmol/kg is about 1.5 to 1.8 mg for a 70 kg adult, given slowly into a vein; online charts list 100 to 300 mcg under the skin, a dose and route never studied. See our DSIP dosage guide.

Grade. B, with results that point to no reliable benefit.

Legal status and cost. Not compoundable. FDA's advisory committee voted 6 to 7, with one abstention, against it on July 24, 2026, for insomnia, narcolepsy and opioid withdrawal. No legal product exists.

Who it is for. Nobody.

3. Epitalon: nominated for insomnia, never tested on sleep

What it does. Epitalon (Ala-Glu-Asp-Gly) is a synthetic four-amino-acid peptide modeled on a Russian pineal-gland extract and sold mostly as a longevity product. Its sleep pitch rests on melatonin, the pineal hormone that signals night.

The key evidence. FDA reviewed epitalon for insomnia in 2026 and found no study of it in people with insomnia, by any route. The human data are two small studies of sublingual epitalon in night-shift workers; in one, 40 women aged 40 to 50 with low melatonin output used a spray or placebo for 20 days, and a urinary melatonin metabolite rose 1.7-fold, but sleep was not measured and blinding was not described. In old female rhesus monkeys, ten daily injections raised evening melatonin more than fourfold; no one recorded their sleep, and FDA found no animal study of epitalon and sleep at all. Rat pineal glands bathed in epitalon did not release more melatonin, and low melatonin has not been consistently linked to insomnia in older adults (FDA epitalon review 2026). The academy suggests against melatonin itself for chronic insomnia (Sateia 2017).

Grade. D. A rise in a melatonin marker is not a sleep outcome.

Legal status and cost. Not compoundable. FDA's reviewers found a lack of evidence for insomnia; its advisory committee nonetheless voted 7 to 4, with one abstention, to recommend epitalon on July 24, 2026, and no pharmacy may make it until FDA completes rulemaking. Websites FDA reviewed list 5 to 10 mg a day by injection or by mouth, doses with no human sleep data.

Who it is for. Nobody, until a sleep trial exists.

4. CJC-1295 and ipamorelin: borrowed physiology, wrong delivery

What they do. CJC-1295 is a modified GHRH; the common version "with DAC" binds to albumin in the blood and lasts about eight days. Ipamorelin is a short-acting ghrelin-receptor agonist. Both raise growth hormone, and clinics sell them together as a sleep stack.

The key evidence. None: no study has measured sleep with either peptide. The claim borrows from GHRH physiology, which argues against the long-acting form. Pulses of GHRH increased slow-wave sleep while a continuous infusion did not (Marshall 1996), and one injection of CJC-1295 with DAC is a continuous stimulus that, a week later, had raised the troughs between growth hormone pulses 7.5-fold while leaving pulse frequency and size unchanged (Ionescu 2006). The no-DAC version and ipamorelin are short-acting, but neither has been tested on sleep, and the no-DAC version has no published human study at all. Our CJC-1295 for sleep guide covers the physiology, including the mixed sleep effects of ipamorelin's drug class.

Grade. D.

Legal status and cost. Not compoundable. FDA's committee voted against ipamorelin in October 2024 and against every form of CJC-1295 in December 2024; FDA now lists both as nominated but withdrawn, which gives no basis for compounding. See the CJC-1295 and ipamorelin profile.

Who it is for. Nobody, legally or evidentially.

Not ranked: MK-677 is not a peptide

MK-677 (ibutamoren) is sold alongside sleep peptides and has the best sleep data of anything on those menus. In a double-blind crossover in eight adults aged 18 to 30, a week of 25 mg at bedtime increased stage IV deep sleep by about 50% and REM sleep by more than 20% against placebo; in six adults aged 65 to 71, studied without a placebo period, REM sleep rose by nearly 50% (Copinschi 1997).

That is a B for sleep, from 14 people, almost 30 years ago. MK-677 is an oral small molecule, not a peptide; it raised fasting glucose in a two-year trial (see the CJC-1295 profile); and it remains in FDA's Category 2 of substances that may present significant safety risks, after the committee voted 1 to 13 against it in October 2024. No pharmacy may compound it.

What we excluded and why

• Melatonin and ramelteon. Melatonin is a hormone, not a peptide. The academy suggests against it for chronic insomnia and gives ramelteon, the prescription melatonin-receptor drug, a weak recommendation for trouble falling asleep (Sateia 2017).
• The orexin antagonists. Small molecules, not peptides; they are the benchmark above.
• Selank and semax. Sold for anxiety and focus with sleep claims attached; we found no insomnia trial of either, and neither can be compounded.
• GHRP-2, GHRP-6 and hexarelin. Older ghrelin-receptor agonists with no insomnia trial and inconsistent laboratory sleep effects (see CJC-1295 for sleep).
• Growth hormone itself. Not a sleep treatment, and distributing it for anti-aging is a federal crime.
• Sleep stacks. Combinations of DSIP, CJC-1295, ipamorelin or epitalon have never been tested together, and none of the components can be compounded.

See a sleep clinician first if any of this sounds familiar

A peptide, like any sedative, can hide a sleep disorder that needs its own treatment. Chronic insomnia means trouble sleeping at least three nights a week for three months or longer (FDA epitalon review 2026), and it deserves an evaluation before anything is injected. See a clinician, ideally one trained in sleep medicine, if you have:

• Loud snoring, pauses in breathing that someone has seen, waking up gasping, morning headaches or sleepiness while driving. These suggest obstructive sleep apnea, diagnosed with a sleep study and treated by keeping the airway open. Get the sleep study before you try any sleep product.
• An urge to move your legs in the evening, with crawling or aching sensations that ease when you move. That is restless legs syndrome, often linked to low iron and treatable in its own right.
• Sudden sleep attacks in the daytime, or muscle weakness when you laugh. These point to narcolepsy, a disorder of the orexin system.
• Acting out dreams, kicking or shouting in your sleep.
• Insomnia alongside low mood, anxiety, chronic pain, heavy drinking or a new medication. Treating the cause often treats the sleep.

How to get treatment that works

CBT-I is delivered by psychologists and other clinicians trained in behavioral sleep medicine, in person or by video, and a primary care clinician can refer you. An orexin antagonist or another hypnotic needs a prescription and a conversation about next-day drowsiness, alcohol and driving. Sermorelin is the only peptide on this list a clinician can prescribe; a legitimate program names the 503A pharmacy, checks IGF-1 at baseline and at 8 to 12 weeks, and does not promise better sleep. DSIP, epitalon, CJC-1295, ipamorelin and MK-677 have no legal source in October 2026.

Bottom line

Ranked honestly, the best "peptide for sleep" is not on the list. CBT-I comes first, and when medication is needed, approved drugs that block the orexin peptide have randomized trials in thousands of people. Among the peptides sold for sleep, sermorelin is the only one with a legal path, and its sleep benefit is an inference from GHRH studies in young men that did not hold up in older adults or women. DSIP was tested and failed to replicate; epitalon, CJC-1295 and ipamorelin were never tested; MK-677 is not a peptide and sits on FDA's safety-risk list. Start with the evaluation and the therapy that work, and treat any peptide as a long shot rather than a plan.

Frequently asked questions

+−Do peptides help with sleep?

Not in any way that has been proven. The only peptide tested in people with insomnia, DSIP, gave positive results in small 1980s studies from one group that independent double-blind studies did not confirm. GHRH, the hormone sermorelin copies, increased deep sleep when given in repeated intravenous pulses to young men, but a GHRH-analog trial in older adults found no change in sleep quality and GHRH impaired sleep in young women. Epitalon, CJC-1295 and ipamorelin have never been tested on sleep. Cognitive behavioral therapy for insomnia and FDA-approved medications have far stronger evidence.

+−What is the best peptide for sleep?

If best means legal and backed by some physiology, sermorelin: a licensed pharmacy can dispense it on prescription, and pulses of GHRH raised slow-wave sleep in small laboratory studies of young men. But no sermorelin trial has measured sleep objectively, and the evidence in older adults and in women is neutral or negative. The best treatment for chronic insomnia is not a peptide at all. It is CBT-I, followed when needed by approved medications such as the orexin antagonists, which block the wake-promoting peptide orexin.

+−Does DSIP work for sleep?

The evidence is small, old and split. Intravenous DSIP improved sleep in studies of 6 to 18 insomniacs run by one Swiss investigator in the 1980s, but those studies compared patients mainly with their own baseline, and two independent double-blind studies found little or no benefit over placebo. Nothing has been published since 1992. FDA's 2026 review called the insomnia evidence inconclusive and at best preliminary, and its advisory committee voted 6 to 7 against allowing DSIP to be compounded.

+−Is epitalon good for sleep?

There is no evidence that it is. FDA reviewed epitalon for insomnia in 2026 and found no study of it in people with insomnia. Its sleep claim rests on melatonin: evening melatonin rose in old monkeys given ten daily injections, and a urinary melatonin marker rose 1.7-fold in 40 middle-aged women who used a sublingual spray for 20 days, but neither study measured sleep. FDA's advisory committee voted 7 to 4 to recommend it for compounding in July 2026, against its reviewers' advice; FDA has not acted, so no US pharmacy may make it.

+−Does CJC-1295 help with deep sleep?

No study has measured sleep in anyone taking CJC-1295 or ipamorelin. The claim is borrowed from GHRH research, in which four intravenous pulses of GHRH increased deep sleep in young men while the same dose given continuously did not. CJC-1295 with DAC lasts about eight days and stimulates the pituitary continuously, which is the pattern that did least for sleep, and the short-acting version without DAC has never been studied in humans. Neither form can be legally compounded in the United States.

+−Is MK-677 a peptide?

No. MK-677 (ibutamoren) is an oral small molecule that activates the ghrelin receptor, the same target as ipamorelin. It is sold alongside peptides and did improve deep and REM sleep in a small 1997 study, but it raised fasting blood sugar in a two-year trial, has never been approved, and remains on FDA's Category 2 list of substances that may present significant safety risks, so no US pharmacy may compound it.

+−What's the downside of taking peptides for sleep?

Three downsides. First, the evidence: no peptide has been shown to treat insomnia. Second, the product: DSIP, epitalon, CJC-1295 and ipamorelin cannot be legally compounded, so what is sold is an unregulated vial with unverified contents, sterility and dose. Third, delay: an injection can mask sleep apnea, restless legs or depression and postpones treatments that work. Growth hormone secretagogues add their own risks, including fluid retention, joint pain and higher blood sugar.

+−Which vitamins or supplements are beneficial for sleep quality?

None has strong evidence for chronic insomnia. In its 2017 drug guideline the American Academy of Sleep Medicine suggested that clinicians not use melatonin, L-tryptophan or valerian for chronic insomnia, and it did not recommend any supplement. The treatment with the strongest evidence, cognitive behavioral therapy for insomnia, involves no pill at all.

+−What are the best peptides for sleep and recovery?

No peptide has been shown to improve either. The recovery pitch for growth hormone secretagogues rests on the fact that the largest growth hormone pulse comes in early deep sleep, but no trial of sermorelin, CJC-1295 or ipamorelin has measured sleep or recovery as an outcome in healthy adults. Sleeping enough and treating any sleep disorder will do more for recovery than any vial; for a documented low IGF-1, sermorelin is the prescribable option, with labs before and after.

Sources

1. GuidelineEdinger JD et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2021;17:255-62. (2021)
2. ReviewTrauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med 2015;163:191-204. (2015)
3. GuidelineSateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2017;13:307-49. (2017)
4. StudyMichelson D et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:461-71. (2014)
5. StudyRosenberg R et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial (SUNRISE 1). JAMA Netw Open 2019;2:e1918254. (2019)
6. StudyMignot E et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 2022;21:125-39. (2022)
7. StudySteiger A et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology 1992;56:566-73. (1992)
8. StudyMarshall L et al. Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). J Clin Endocrinol Metab 1996;81:1009-13. (1996)
9. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
10. StudyMathias S et al. Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology 2007;32:1021-7. (2007)
11. StudyBes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992;26:193-7. (1992)
12. StudyCopinschi G et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997;66:278-86. (1997)
13. StudyIonescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792-7. (2006)
14. RegulatoryFDA. Briefing document for emideltide-related bulk drug substances (emideltide free base and emideltide acetate), Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026. (2026)
15. RegulatoryFDA. Briefing document for epitalon-related bulk drug substances (epitalon free base and epitalon acetate), evaluated for insomnia, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026. (2026)